CapsoVision Inc (CV) Stock News

BioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor for cardiovascular risk reduction. The randomized, double-blind, placebo-controlled trial will enroll approximately 160 participants with obesity and elevated inflammation across three dose levels. Phase 1 results showed BGE-102 achieved median hsCRP reductions of 86% and was well tolerated. Topline data are anticipated in the second half of 2026, with an additional Phase 1b/2a trial in diabetic macular edema planned for mid-2026.

Mizuho analyst Ann Hynes raised her CVS Health price target to $115 per share, implying 13% upside from current levels. The article suggests CVS could see even greater upside potential, potentially reaching $150 per share if it achieves a valuation multiple similar to UnitedHealth Group, given its transformation into a diversified healthcare services company and expected double-digit earnings growth.

Law Offices of Howard G. Smith announced securities fraud class action lawsuits against four publicly-traded companies. Phreesia Inc. faces allegations of misrepresenting growth projections, Sportradar Group AG is accused of working with black-market gambling operators while claiming compliance, Commvault Systems Inc. allegedly failed to properly account for sales type impacts on ARR growth, and Veritone Inc. is charged with revenue misclassification and deficient internal controls. Investors have until mid-July 2026 to file lead plaintiff motions.

XOMA Royalty Corporation announced quarterly preferred stock dividends for Series A and Series B preferred shareholders, with Series A receiving $0.53906 per share and Series B receiving $0.52344 per depositary share, payable on July 15, 2026. The company also announced the redemption of all outstanding preferred stock at $25.00 per share on July 14, 2026, in connection with its pending merger with Ligand Pharmaceuticals through Flex Merger Sub, Inc. Additionally, the record date for CVR distribution to common stockholders has been set for July 13, 2026.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Phreesia Inc., Sportradar Group AG, Commvault Systems Inc., and Veritone Inc. Investors have until mid-July 2026 to file lead plaintiff motions. The complaints allege various forms of misrepresentation including false growth projections, undisclosed compliance violations, misleading revenue guidance, and accounting irregularities.

Rosen Law Firm is soliciting investors who purchased securities of Commvault Systems (CVLT) between April 29, 2025 and January 26, 2026 to join a class action lawsuit. The lawsuit alleges that Commvault provided false and misleading statements regarding ARR growth guidance while concealing material adverse facts. The lead plaintiff deadline is July 17, 2026. Similar class action notices are being issued for Calix, Inc. and FLOW cryptocurrency.

Chevron reported Q1 2026 earnings that fell 35% year-over-year due to hedging timing headwinds, but underlying fundamentals were strong. The company increased U.S. production 24% following the Hess acquisition and returned $6 billion to shareholders through dividends and buybacks. While the company benefits from elevated oil prices driven by Middle East geopolitical tensions, investors should be cautious about buying based solely on current high oil prices, as sentiment-driven volatility could reverse if the conflict ends.

Chevron (CVX) is a highly leveraged bet on crude oil prices and geopolitical risk in the Strait of Hormuz. The stock has declined from $214.71 to $188 as oil prices fell 20% on ceasefire hopes between the U.S. and Iran. While CVX offers a fortress dividend with 39 years of consecutive growth and a reasonable 14x forward P/E multiple, its earnings are heavily dependent on oil prices remaining elevated. The stock faces a binary outcome: if the ceasefire holds, crude falls and CVX declines further; if talks collapse, crude spikes and CVX rallies significantly. Notable headwinds include Berkshire Hathaway's 35% stake reduction and insider selling.

Rosen Law Firm is encouraging investors who purchased securities of Commvault Systems, Calix, Inc., and Wise Group plc during specified periods to join class action lawsuits. The Commvault lawsuit alleges the company made materially false statements regarding ARR growth guidance and concealed material adverse facts. Lead plaintiff deadlines and contingency fee arrangements are available for eligible investors.

Rosen Law Firm is soliciting investors to join securities class action lawsuits against Commvault Systems, ChampionX Corporation, and Regencell Bioscience Holdings. The firm reminds investors of upcoming lead plaintiff deadlines and offers contingency-based legal representation. The lawsuits allege that defendants made materially false statements and concealed adverse facts regarding financial performance.

CVS Health's dividend is sustainable despite the company pausing annual increases. With Q1 2026 operating cash flow of $4.2 billion and expected annual cash flow of at least $9.5 billion, CVS comfortably covers its $3.39 billion projected dividend payout (representing just over 20% of cash flow). The company's 2.89% dividend yield significantly exceeds the S&P 500 average, making it an attractive income investment with minimal risk of elimination.

H1, an AI-powered healthcare platform for identifying and engaging physicians, secured a $40M investment led by CVS Health Ventures. The funding follows successful collaborations between the companies, including an AI model that improved healthcare provider directory accuracy. H1 serves 85% of top 20 pharma companies and 9 out of 10 top health plans, and is on track to achieve above Rule of 40 profitability metrics in 2026.

The iShares Morningstar Small-Cap Value ETF (ISCV) has outperformed the iShares S&P Mid-Cap 400 Value ETF (IJJ) over the past year with a 30.94% return versus 22.25%, driven by small-cap optimism around domestic growth and deregulation. However, ISCV carries higher volatility with a deeper maximum drawdown of 25.30% compared to IJJ's 22.70%. ISCV offers a lower expense ratio of 0.06% versus IJJ's 0.18%, making it attractive for cost-conscious investors, though IJJ provides greater stability and liquidity with its larger asset base.

Despite Brent crude oil rising 85% in 2026 due to Middle East geopolitical tensions, Occidental Petroleum, ExxonMobil, and Chevron benefited unevenly in Q1. Timing of the oil price spike (occurring mainly in March), regional exposure differences, and hedging activities created headwinds. Oxy beat expectations with $1.06 EPS vs. $0.59 expected, while Exxon earned $1.16 vs. $1.01 expected and Chevron earned $1.41 vs. $0.97 expected, but both faced significant hedging charges. Q2 expectations are substantially higher.

CVS Health stock has surged 24% over the past month following strong Q1 earnings that beat analyst expectations, with revenue up 6.2% to $100.4B and EPS up 62% to $2.30. The company raised full-year guidance and is benefiting from improved margins in its Aetna insurance segment and growth from Rite Aid store acquisitions. However, the company carries significant debt of $86.4B in long-term obligations, though it is gradually reducing overall leverage.

Rosen Law Firm has filed class action lawsuits against Commvault Systems, Inc. (CVLT) on behalf of investors who purchased securities between April 29, 2025 and January 26, 2026. The lawsuit alleges that Commvault provided materially false and misleading statements regarding ARR growth guidance while concealing material adverse facts. Investors have until July 17, 2026 to move the court to serve as lead plaintiff. Similar class action investigations are ongoing for PennyMac Financial Services and ChampionX Corporation.

CVD Equipment (NASDAQ:CVV) shares fell 17.66% in after-hours trading after reporting a steep 70.9% revenue decline to $1.8 million in Q1 2026, wider net losses, and continued pressure from geopolitical uncertainty and lower university funding. However, the company completed the sale of its SDC division generating $14.8 million in cash proceeds, improving its balance sheet with $23 million in cash and no long-term debt.

Maticmind SpA said all its published financial information is “complete and correct” as it sought to reassure investors after a fraud probe into the software firm’s founder sent its bonds sliding.